Find verified Ipilimumab API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Ipilimumab for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Ipilimumab API.
Alternate Names: anti-CTLA-4, MDX-010, SY028004
CAS No: 477202-00-9
PubChem CID: 167312542
Mol Formula: C162H204O17S9
Mol Weight: 2712 g/mol
IUPAC Name: 3-butyl-4-hydroxy-5-methyl-5-(2-methylbuta-1,3-dienyl)thiophen-2-one;4-ethyl-2-methyl-2-(2-methylbuta-1,3-dienyl)-5-methylidenethiophen-3-ol;tetrakis( -Show More
Therapeutic use: Anti-cancer agents
Drug Class: Checkpoint inhibitors
Commercial / Development Status: Commercial APIs
Source / Manufacturing Origin: Peptide APIs
API Description: Ipilimumab is a monoclonal antibody used as an immunotherapy drug that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). By blocking CTLA-4, it enhances the body’s immune response against cancer cells. It is primarily used to treat advanced melanoma, renal cell carcinoma, and certain other cancers, either alone or in combination with other immunotherapies. Ipilimumab is administered via intravenous infusion under strict clinical supervision due to potential immune-related side effects.
